On Monday, Shares of Rocket Fuel Inc (NASDAQ:FUEL), lost -2.34% to $4.60.
Rocket Fuel, published new findings on the impact of tourism video and display ads. The findings revealed that travelers who watched tourism video ads to completion were 23 times more likely to book a hotel in a destination city advertised. While consumers who saw only display ads were still three times more likely to book a hotel in the destination city, those who saw video ads were nearly 20 times more likely to book a trip. The findings are based on an analysis of Rocket Fuel data from a recent tourism ad campaign with a regional convention and visitor’s bureau.
“Billions are spent digitally in the highly competitive travel market, yet video is underutilized, mainly due to perceived costs,” said Chris Lorenzoni, Rocket Fuel’s director of category strategy for travel. “Rocket Fuel’s latest findings from travel campaign data reinforce that an investment in programmatic video ads, in tandem with display, can drive real results.”
Rocket Fuel Inc., a technology company, provides artificial-intelligence digital advertising solutions. The company’s artificial intelligence-driven technology platform is built on its real-time optimization engine, which leverages Big Data and its computational infrastructure to purchase and deliver highly-automated digital advertising campaigns.
Shares of Arcos Dorados Holding Inc (NYSE:ARCO), declined -1.37% to $2.89, during its last trading session.
Arcos Dorados has teamed up with McDonald’s and other global brands to highlight the importance of food assistance for families affected by war. The Company is actively promoting the United Nations World Food Programme (WFP) through its social medial channels across Latin America, where it is the largest restaurant chain.
WFP, which is the frontline agency fighting hunger, will use money raised by this multi-industry effort to assist support refugees and displaced people struggling daily to feed their families. The campaign has drawn support from major brands, such as McDonald’s, Google, Facebook, MasterCard and United Airlines through donations of their media and social outlets. The United Nations is bringing further attention to the issue of food aid as the number of families affected by war continues to rise and humanitarian resources become stretched.
Arcos Dorados, which is the world’s largest McDonald’s franchisee, is using its social media channels, counting Facebook and Twitter, across its operating regions to promote donations to WFP as part of the campaign held on the International Day of Peace. This comprises the Company’s social media coverage in Brazil, Mexico, Argentina, Chile, Panama, Venezuela and Puerto Rico, in addition to other Latin American and Caribbean countries.
Arcos Dorados Holdings Inc. is a McDonald’s franchisee. The Company, through its wholly owned and majority owned auxiliaries, operates and franchises McDonald’s restaurants in the food service industry.
At the end of Monday’s trade, Shares of CONN’S, Inc. (NASDAQ:CONN), lost -2.57% to $24.30.
Furniture and specialty home goods retailer Conn’s, celebrated the grand opening of its first Georgia store in Augusta on Saturday, September 26. The event featured gift card giveaways, storewide promotions and an opportunity for local customers to enter to win a $10,000 shopping spree.
Conn’s HomePlus offers high-quality and affordable products, specializing in furniture and mattresses, home appliances, consumer electronics and home office products.
The new 50,000 square-foot Conn’s HomePlus at 270 Bobby Jones Expressway in Augusta is one of the largest store formats in the chain and has created almost 30 local jobs for the area. The store is part of Conn’s robust national growth strategy to open nearly 20 stores during a 12-month period (February 2015–February 2016). Conn’s, which has a brick-and-mortar presence in 12 states, will open its 100th store next month.
Conn’s, Inc. operates as a specialty retailer of durable consumer goods and related services in the United States. It operates through Retail and Credit segments. The company’s stores provide home appliance comprising refrigerators, freezers, washers, dryers, dishwashers, and ranges; home furniture and mattress, counting furniture and related accessories for the living room, dining room, and bedroom, in addition to traditional and specialty mattresses; and home office products compriseing of computers, tablets, printers, and accessories.
Finally, Chimerix Inc (NASDAQ:CMRX), ended its last trade with -9.55% loss, and closed at $38.66.
Chimerix, Inc. (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, presented findings from a new study that show hospital readmissions related to opportunistic infections are common among patients following autologous and allogeneic hematopoietic cell transplant (HCT), also known as bone marrow or stem cell transplant. The study showed that of hospital readmissions related to opportunistic infections (25.8 percent of all readmissions), about 1 in 3 readmissions were due to double-stranded DNA (dsDNA) viral infections. Among dsDNA viral infections diagnosed after hospital discharge, almost half occurred within the first month after discharge. The study also showed that the majority of hospital readmissions among HCT recipients were major or extreme in severity. These data were presented during the 55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego.
“This is the first in a series of research studies we will be presenting that highlight the incidence and impact of dsDNA viruses in HCT and kidney transplant populations, in addition to the associated healthcare costs of viral reactivation and hospital readmissions,” said W. Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix. “These data emphasize how fragile patients are following HCT, and the limitations of current treatments for dsDNA viruses. Because data show that these infections typically happen during the transplant hospitalization or soon after patients are discharged, medicines that may prevent viral reactivation and resulting hospital readmissions could play a critical role in the treatment of HCT patients and may potentially reduce the economic burden to the patient, their families and the healthcare system.”
This study evaluated data from 2009-2013 in the Premier Hospital Database based on documented ICD-9-CM codes in the health records.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds comprise brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, in addition to to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.